Pub Date : 2026-02-01Epub Date: 2025-08-30DOI: 10.1007/s00259-025-07521-7
Silvia Carraro, Valentina A Ferraro, Pietro Zucchetta, Stefania Zanconato, Francesca Serani, Chiara Giraudo, Diego Cecchin
Background: Primary ciliary dyskinesia (PCD) is a rare condition characterized by ciliary dysfunction, impaired mucociliary clearance and mucus accumulation in the airways.
Purpose: Our aim was to evaluate the performance of [18F]FDG PET/MR in assessing structural and inflammatory pulmonary features in patients with PCD, using high-resolution CT (HRCT) as the gold-standard reference.
Materials and methods: We recruited patients with PCD (≥ 7 years) regularly followed at our Regional Center for PCD. They underwent chest HRCT and [18F]FDG PET/MR using sequences optimized for the morpho-functional study of the lung. Parametric PET images were obtained by dividing each voxel by the mean value in a reference area. The volume of interest (VOI in cm3), named Metabolic Inflammatory Volume (MIV), was calculated by thresholding the PET parametric image using a value twice the mean of the reference area. Standardized Uptake Value (SUV) Max, SUV mean, Total Lesion Glycolysis (TLG) and MIV were recorded. HRCT and MR were analyzed using the Eichinger score.
Results: Sixteen patients were enrolled. The Bland-Altman plot showed good agreement between HRCT and MR scores. Cumulative HRCT and MR scores correlated significantly with SUV mean score (HRCT: p = 0.02, rs=0.6; MR: p = 0.006, rs=0.66) and MIV (HRCT: p = 0.003, rs =0.7; MR: p = 0.004, rs =0.69). Total HRCT and MR scores and MIV score inversely correlated with spirometric parameters.
Conclusion: PET/MR proved to be accurate in evaluating disease extent in PCD. It enabled the simultaneous assessment of structural damage and lung inflammation, both of which resulted inversely related to lung function. PET/MR is a promising tool for PCD monitoring.
背景：原发性纤毛运动障碍（PCD）是一种罕见的疾病，其特征是纤毛功能障碍，纤毛粘膜清除受损和气道粘液积聚。目的：我们的目的是评估[18F]FDG PET/MR在评估PCD患者肺部结构和炎症性特征方面的表现，以高分辨率CT （HRCT）作为金标准参考。材料和方法：我们招募了PCD患者（≥7年），在我们的PCD区域中心定期随访。他们接受了胸部HRCT和[18F]FDG PET/MR，使用优化的肺部形态功能研究序列。参数化PET图像由每个体素除以参考区域的平均值得到。感兴趣的体积（VOI，以cm3为单位），称为代谢炎症体积（MIV），通过使用参考区域平均值的两倍的值对PET参数图像进行阈值计算。记录标准化摄取值（SUV） Max、SUV均值、病灶糖酵解总量（TLG）和MIV。采用Eichinger评分对HRCT和MR进行分析。结果：16例患者入组。Bland-Altman图显示HRCT和MR评分吻合良好。累积HRCT和MR评分与SUV平均评分（HRCT: p = 0.02, rs=0.6; MR: p = 0.006, rs=0.66）和MIV （HRCT: p = 0.003, rs= 0.7; MR: p = 0.004, rs= 0.69）显著相关。HRCT和MR总评分及MIV评分与肺量测定参数呈负相关。结论：PET/MR能准确评价PCD病变程度。它可以同时评估结构损伤和肺部炎症，两者的结果与肺功能呈负相关。PET/MR是一种很有前途的PCD监测工具。
{"title":"[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia.","authors":"Silvia Carraro, Valentina A Ferraro, Pietro Zucchetta, Stefania Zanconato, Francesca Serani, Chiara Giraudo, Diego Cecchin","doi":"10.1007/s00259-025-07521-7","DOIUrl":"10.1007/s00259-025-07521-7","url":null,"abstract":"<p><strong>Background: </strong>Primary ciliary dyskinesia (PCD) is a rare condition characterized by ciliary dysfunction, impaired mucociliary clearance and mucus accumulation in the airways.</p><p><strong>Purpose: </strong>Our aim was to evaluate the performance of [18F]FDG PET/MR in assessing structural and inflammatory pulmonary features in patients with PCD, using high-resolution CT (HRCT) as the gold-standard reference.</p><p><strong>Materials and methods: </strong>We recruited patients with PCD (≥ 7 years) regularly followed at our Regional Center for PCD. They underwent chest HRCT and [18F]FDG PET/MR using sequences optimized for the morpho-functional study of the lung. Parametric PET images were obtained by dividing each voxel by the mean value in a reference area. The volume of interest (VOI in cm<sup>3</sup>), named Metabolic Inflammatory Volume (MIV), was calculated by thresholding the PET parametric image using a value twice the mean of the reference area. Standardized Uptake Value (SUV) Max, SUV mean, Total Lesion Glycolysis (TLG) and MIV were recorded. HRCT and MR were analyzed using the Eichinger score.</p><p><strong>Results: </strong>Sixteen patients were enrolled. The Bland-Altman plot showed good agreement between HRCT and MR scores. Cumulative HRCT and MR scores correlated significantly with SUV mean score (HRCT: p = 0.02, r<sub>s</sub>=0.6; MR: p = 0.006, r<sub>s</sub>=0.66) and MIV (HRCT: p = 0.003, r<sub>s</sub> =0.7; MR: p = 0.004, r<sub>s</sub> =0.69). Total HRCT and MR scores and MIV score inversely correlated with spirometric parameters.</p><p><strong>Conclusion: </strong>PET/MR proved to be accurate in evaluating disease extent in PCD. It enabled the simultaneous assessment of structural damage and lung inflammation, both of which resulted inversely related to lung function. PET/MR is a promising tool for PCD monitoring.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2158-2166"},"PeriodicalIF":7.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Purpose: </strong>Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [<sup>68</sup>Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp<sub>2</sub>-PEG<sub>2</sub>- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.</p><p><strong>Methods: </strong>Asp<sub>2</sub>-JR11 was synthesized by modifying the NOTA-JR11 backbone, and its binding properties were evaluated via molecular docking, in vitro assays, and in vivo imaging. Radiolabeling with <sup>68</sup>Ga was performed for Asp<sub>2</sub>-JR11, NOTA-JR11, and DOTA-TATE. We conducted cell uptake, internalization, PET/CT imaging, biodistribution, and blocking studies in AR42J (SSTR2-positive) and HCT116 (SSTR2-negative) tumor models. A first-in-human study included nine patients with NENs who underwent [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 PET/CT and [<sup>18</sup>F]FDG PET/CT imaging, along with dosimetry assessment.</p><p><strong>Results: </strong>Docking analysis showed that Asp<sub>2</sub>-JR11 maintained equivalent binding energy to NOTA-JR11 but formed more hydrogen bonds with SSTR2 (10 vs. 5), suggesting enhanced stability. [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 demonstrated high radiochemical purity (> 95%), higher molar activity (12.9-14.8 GBq/µmol), and greater hydrophilicity (LogD = - 3.18 ± 0.01) than comparators. In AR42J cells, [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 exhibited rapid uptake (9.95 ± 0.10%AD/10⁶ cells at 30 min) and low internalization (17.63 ± 0.91% at 120 min), with significantly higher uptake than [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-NOTA-JR11 in both in vitro and micro PET/CT studies (e.g., 10.67 ± 0.16 vs. 7.79 ± 0.50%ID/g at 30 min, p < 0.05). In vivo imaging and biodistribution confirmed higher tumor-to-background ratios and reduced off-target organ uptake, notably in the kidneys, pancreas, and spleen. Tumor uptake was significantly inhibited by co-injection of SSTR2 ligands, confirming specificity. In human subjects, [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 showed favorable biodistribution and rapid clearance via renal excretion, with the spleen showing the highest transient uptake. Tumors were clearly visualized as early as 12 min post-injection and maintained strong contrast up to 120 min. Dosimetry revealed the highest absorbed dose in the urinary bladder wall (5.78 × 10⁻² mSv/MBq), with an effective whole-body dose of 9.94 × 10⁻³ mSv/MBq. Comparative PET/CT imaging in nine patients (33
{"title":"Synthesis, preclinical evaluation, and clinical translation of [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.","authors":"Zihao Chen, Xingyu Mu, Lei Zhang, Zhisheng Jie, Kadeer Tudi, Haoran Liang, Qingxing Liu, Jingze Li, Weixia Chong, Yufeng Mo, Wei Fu, Ganghua Tang","doi":"10.1007/s00259-025-07474-x","DOIUrl":"10.1007/s00259-025-07474-x","url":null,"abstract":"<p><strong>Purpose: </strong>Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [<sup>68</sup>Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp<sub>2</sub>-PEG<sub>2</sub>- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.</p><p><strong>Methods: </strong>Asp<sub>2</sub>-JR11 was synthesized by modifying the NOTA-JR11 backbone, and its binding properties were evaluated via molecular docking, in vitro assays, and in vivo imaging. Radiolabeling with <sup>68</sup>Ga was performed for Asp<sub>2</sub>-JR11, NOTA-JR11, and DOTA-TATE. We conducted cell uptake, internalization, PET/CT imaging, biodistribution, and blocking studies in AR42J (SSTR2-positive) and HCT116 (SSTR2-negative) tumor models. A first-in-human study included nine patients with NENs who underwent [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 PET/CT and [<sup>18</sup>F]FDG PET/CT imaging, along with dosimetry assessment.</p><p><strong>Results: </strong>Docking analysis showed that Asp<sub>2</sub>-JR11 maintained equivalent binding energy to NOTA-JR11 but formed more hydrogen bonds with SSTR2 (10 vs. 5), suggesting enhanced stability. [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 demonstrated high radiochemical purity (> 95%), higher molar activity (12.9-14.8 GBq/µmol), and greater hydrophilicity (LogD = - 3.18 ± 0.01) than comparators. In AR42J cells, [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 exhibited rapid uptake (9.95 ± 0.10%AD/10⁶ cells at 30 min) and low internalization (17.63 ± 0.91% at 120 min), with significantly higher uptake than [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-NOTA-JR11 in both in vitro and micro PET/CT studies (e.g., 10.67 ± 0.16 vs. 7.79 ± 0.50%ID/g at 30 min, p < 0.05). In vivo imaging and biodistribution confirmed higher tumor-to-background ratios and reduced off-target organ uptake, notably in the kidneys, pancreas, and spleen. Tumor uptake was significantly inhibited by co-injection of SSTR2 ligands, confirming specificity. In human subjects, [<sup>68</sup>Ga]Ga-Asp<sub>2</sub>-JR11 showed favorable biodistribution and rapid clearance via renal excretion, with the spleen showing the highest transient uptake. Tumors were clearly visualized as early as 12 min post-injection and maintained strong contrast up to 120 min. Dosimetry revealed the highest absorbed dose in the urinary bladder wall (5.78 × 10⁻² mSv/MBq), with an effective whole-body dose of 9.94 × 10⁻³ mSv/MBq. Comparative PET/CT imaging in nine patients (33 ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"1532-1548"},"PeriodicalIF":7.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-31DOI: 10.1007/s00259-026-07777-7
Lidia Gatto,Riccardo Mei,Martina Stasolla,Enrico Zuliani,Vincenzo Di Nunno,Alicia Tosoni,Marta Aprile,Stefania Bartolini,Marzia Margotti,Chiara Maria Argento,Stefano Fanti,Enrico Franceschi
PURPOSEPositron emission tomography (PET) has become an increasingly important adjunct to brain MRI in the field of neuro-oncology. PET imaging utilizes radiolabeled tracers, providing in vivo assessment of the metabolic and molecular characteristics of gliomas, thereby providing functional data beyond standard anatomic images. This additional layer of crucial biological insight aids in personalized patient management and treatment decision. In recent years, numerous studies have been carried out for the development and clinical validation of several PET radiotracers in glioma imaging, leading to a substantial improvement in glioma diagnosis, staging, treatment strategy planning as well as in monitoring tumor progression and response to therapy. Ongoing innovations in radiopharmaceutical design have further improved the diagnostic performance of PET by increasing both tracer specificity and tumor detection sensitivity.METHODSIn this review, we summarize recent developments in PET imaging for glioma, with particular emphasis on clinically available amino acid PET tracers. In addition, we provide an overview of emerging theranostic strategies, including peptide receptor radionuclide therapy (PRRT) for meningioma and 177Lu-PSMA-617-based approaches for high-grade glioma.RESULTSThe current guidelines recommend the use of amino acid PET for differentiation of neoplastic from non-neoplastic lesions, for delineation of glioma extent, for non-invasive prediction of molecular information, for grading and prognosis estimation, for differentiation of glioma relapse from treatment-related changes and for the evaluation of treatment response.CONCLUSIONSOverall, this work aims to highlight the role of PET as a complementary imaging modality to MRI and to discuss its potential impact on patient outcomes in neuro-oncological practice.
{"title":"Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.","authors":"Lidia Gatto,Riccardo Mei,Martina Stasolla,Enrico Zuliani,Vincenzo Di Nunno,Alicia Tosoni,Marta Aprile,Stefania Bartolini,Marzia Margotti,Chiara Maria Argento,Stefano Fanti,Enrico Franceschi","doi":"10.1007/s00259-026-07777-7","DOIUrl":"https://doi.org/10.1007/s00259-026-07777-7","url":null,"abstract":"PURPOSEPositron emission tomography (PET) has become an increasingly important adjunct to brain MRI in the field of neuro-oncology. PET imaging utilizes radiolabeled tracers, providing in vivo assessment of the metabolic and molecular characteristics of gliomas, thereby providing functional data beyond standard anatomic images. This additional layer of crucial biological insight aids in personalized patient management and treatment decision. In recent years, numerous studies have been carried out for the development and clinical validation of several PET radiotracers in glioma imaging, leading to a substantial improvement in glioma diagnosis, staging, treatment strategy planning as well as in monitoring tumor progression and response to therapy. Ongoing innovations in radiopharmaceutical design have further improved the diagnostic performance of PET by increasing both tracer specificity and tumor detection sensitivity.METHODSIn this review, we summarize recent developments in PET imaging for glioma, with particular emphasis on clinically available amino acid PET tracers. In addition, we provide an overview of emerging theranostic strategies, including peptide receptor radionuclide therapy (PRRT) for meningioma and 177Lu-PSMA-617-based approaches for high-grade glioma.RESULTSThe current guidelines recommend the use of amino acid PET for differentiation of neoplastic from non-neoplastic lesions, for delineation of glioma extent, for non-invasive prediction of molecular information, for grading and prognosis estimation, for differentiation of glioma relapse from treatment-related changes and for the evaluation of treatment response.CONCLUSIONSOverall, this work aims to highlight the role of PET as a complementary imaging modality to MRI and to discuss its potential impact on patient outcomes in neuro-oncological practice.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"143 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSELong axial field of view (LAFOV) PET imaging requires extensive automation due to the large number of target tissues. Therefore, we introduce an open-source analysis pipeline (TurBO, Turku total-BOdy) for automated preprocessing and kinetic modelling of LAFOV [15O]H2O and [18F]FDG PET data. TurBO enables efficient, reproducible quantification of tissue perfusion and metabolism at regional- and voxel-levels through automated co-registration, motion correction, CT-based region of interest (ROI) segmentation, image-derived input function (IDIF) extraction, and region-specific kinetic modelling.METHODSThe pipeline was validated with Biograph Vision Quadra (Siemens Healthineers) LAFOV PET/CT data from 21 subjects scanned with [15O]H2O and 16 subjects scanned with [18F]FDG. Six CT-segmented ROIs (cortical brain gray matter, left iliopsoas muscle, right kidney cortex and medulla, pancreas, spleen and liver) were used to assess different levels of tissue perfusion and glucose metabolism.RESULTSModel fits showed high quality with consistent estimates at regional and voxel-levels (R2 > 0.83 for [15O]H2O, R2 > 0.99 for [18F]FDG). Manual and automated IDIFs were in concordance (R2 > 0.74 for [15O]H2O, and R2 > 0.78 for [18F]FDG) with minimal bias (< 4% and < 10%, respectively). Manual and CT-segmented ROIs showed strong agreement (R2 > 0.82 for [15O]H2O and R2 > 0.83 for [18F]FDG). Motion correction had little impact on estimates (R2 > 0.71 for [15O]H2O and R2 > 0.78 for [18F]FDG) compared with uncorrected data.CONCLUSIONThe TurBO pipeline provides fully automated and reliable quantification for LAFOV PET data. It substantially reduces manual workload and enables standardized, reproducible assessment of inter-organ perfusion and metabolism.
{"title":"Automated long axial field of view PET image processing and kinetic modelling with the TurBO toolbox.","authors":"Jouni Tuisku,Santeri Palonen,Henri Kärpijoki,Aino Latva-Rasku,Nelli Tuomola,Harri Harju,Sergey V Nesterov,Vesa Oikonen,Hidehiro Iida,Jarmo Teuho,Chunlei Han,Tomi Karjalainen,Anna K Kirjavainen,Johan Rajader,Riku Klén,Pirjo Nuutila,Juhani Knuuti,Lauri Nummenmaa","doi":"10.1007/s00259-026-07769-7","DOIUrl":"https://doi.org/10.1007/s00259-026-07769-7","url":null,"abstract":"PURPOSELong axial field of view (LAFOV) PET imaging requires extensive automation due to the large number of target tissues. Therefore, we introduce an open-source analysis pipeline (TurBO, Turku total-BOdy) for automated preprocessing and kinetic modelling of LAFOV [15O]H2O and [18F]FDG PET data. TurBO enables efficient, reproducible quantification of tissue perfusion and metabolism at regional- and voxel-levels through automated co-registration, motion correction, CT-based region of interest (ROI) segmentation, image-derived input function (IDIF) extraction, and region-specific kinetic modelling.METHODSThe pipeline was validated with Biograph Vision Quadra (Siemens Healthineers) LAFOV PET/CT data from 21 subjects scanned with [15O]H2O and 16 subjects scanned with [18F]FDG. Six CT-segmented ROIs (cortical brain gray matter, left iliopsoas muscle, right kidney cortex and medulla, pancreas, spleen and liver) were used to assess different levels of tissue perfusion and glucose metabolism.RESULTSModel fits showed high quality with consistent estimates at regional and voxel-levels (R2 > 0.83 for [15O]H2O, R2 > 0.99 for [18F]FDG). Manual and automated IDIFs were in concordance (R2 > 0.74 for [15O]H2O, and R2 > 0.78 for [18F]FDG) with minimal bias (< 4% and < 10%, respectively). Manual and CT-segmented ROIs showed strong agreement (R2 > 0.82 for [15O]H2O and R2 > 0.83 for [18F]FDG). Motion correction had little impact on estimates (R2 > 0.71 for [15O]H2O and R2 > 0.78 for [18F]FDG) compared with uncorrected data.CONCLUSIONThe TurBO pipeline provides fully automated and reliable quantification for LAFOV PET data. It substantially reduces manual workload and enables standardized, reproducible assessment of inter-organ perfusion and metabolism.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"103 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1007/s00259-025-07737-7
Brett W Sperry,Eric Burgett,James A Case,Timothy M Bateman
{"title":"Rapid dynamic acquisition of cardiac amyloid radionuclide imaging.","authors":"Brett W Sperry,Eric Burgett,James A Case,Timothy M Bateman","doi":"10.1007/s00259-025-07737-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07737-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"261 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1007/s00259-026-07775-9
Helmut Rasch,Randa Elsheikh,George M Avram,Alexandra Leica,Sabrina Chelli,Felix Amsler,Andrej M Nowakowski,Rolf Huegli,Michael T Hirschmann
{"title":"SPECT/CT peak tracer uptake is a strong predictor of aseptic loosening in painful total knee arthroplasty.","authors":"Helmut Rasch,Randa Elsheikh,George M Avram,Alexandra Leica,Sabrina Chelli,Felix Amsler,Andrej M Nowakowski,Rolf Huegli,Michael T Hirschmann","doi":"10.1007/s00259-026-07775-9","DOIUrl":"https://doi.org/10.1007/s00259-026-07775-9","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"42 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSEDifferentiating heart failure-related death (HFD) from arrhythmic events (ArEs) is clinically important for patients with chronic heart failure (CHF), as they have distinct mechanisms and therapeutic strategies. We developed and validated a multivariable model to predict HFD, ArEs, and survival using clinical parameters and cardiac 123I-meta-iodobenzylguanidine (123I-mIBG) images.METHODSWe retrospectively analyzed data derived from 997 patients with CHF (mean age 70 ± 13 years, left ventricular ejection fraction (LVEF) 32% ± 13%) over a mean follow-up of 41 ± 27 months. Outcomes were survival, HFD, or ArEs (including sudden cardiac death). Appropriate implantable cardioverter defibrillator therapy for lethal arrhythmias was included in ArEs. Late heart-to-mediastinum ratios (HMRs) were derived from 123I-mIBG images. A multinomial nested logistic regression model using 2 years of outcomes was constructed (N = 854). Internal validation used a 2:1 development-validation split, repeated 3 times. Model performance was assessed by receiver operating characteristic (ROC) analysis, calibration of predicted vs. actual event rates, survival curves, and sex-specific predictive models.RESULTSSelected variables were age, sex, New York Heart Association (NYHA) functional class, LVEF, hemoglobin, estimated glomerular filtration rate, hypertension, ventricular tachycardia history, and late 123I-mIBG HMR. Areas under ROC curves for survival, HFD, and ArEs in the final 9-variable model were 0.800, 0.717, and 0.838, respectively. The sex-specific 7-variable models showed comparable AUCs of 0.834/0.827 (male/female) for HFD and 0.714/0.826 for ArEs. Risk groups based on median predicted probabilities of HFD and ArEs separated survival curves and corresponded well with actual outcomes.CONCLUSIONSA practical, interpretable model incorporating clinical and 123I-mIBG imaging data enabled reliable and separate prediction of HFD and ArEs, supporting personalized risk stratification in CHF.
{"title":"Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model.","authors":"Kenichi Nakajima,Takahiro Doi,Tomoaki Nakata,Takuya Nakahashi,Hayato Tada,Hiroshi Wakabayashi,Hein J Verberne","doi":"10.1007/s00259-026-07776-8","DOIUrl":"https://doi.org/10.1007/s00259-026-07776-8","url":null,"abstract":"PURPOSEDifferentiating heart failure-related death (HFD) from arrhythmic events (ArEs) is clinically important for patients with chronic heart failure (CHF), as they have distinct mechanisms and therapeutic strategies. We developed and validated a multivariable model to predict HFD, ArEs, and survival using clinical parameters and cardiac 123I-meta-iodobenzylguanidine (123I-mIBG) images.METHODSWe retrospectively analyzed data derived from 997 patients with CHF (mean age 70 ± 13 years, left ventricular ejection fraction (LVEF) 32% ± 13%) over a mean follow-up of 41 ± 27 months. Outcomes were survival, HFD, or ArEs (including sudden cardiac death). Appropriate implantable cardioverter defibrillator therapy for lethal arrhythmias was included in ArEs. Late heart-to-mediastinum ratios (HMRs) were derived from 123I-mIBG images. A multinomial nested logistic regression model using 2 years of outcomes was constructed (N = 854). Internal validation used a 2:1 development-validation split, repeated 3 times. Model performance was assessed by receiver operating characteristic (ROC) analysis, calibration of predicted vs. actual event rates, survival curves, and sex-specific predictive models.RESULTSSelected variables were age, sex, New York Heart Association (NYHA) functional class, LVEF, hemoglobin, estimated glomerular filtration rate, hypertension, ventricular tachycardia history, and late 123I-mIBG HMR. Areas under ROC curves for survival, HFD, and ArEs in the final 9-variable model were 0.800, 0.717, and 0.838, respectively. The sex-specific 7-variable models showed comparable AUCs of 0.834/0.827 (male/female) for HFD and 0.714/0.826 for ArEs. Risk groups based on median predicted probabilities of HFD and ArEs separated survival curves and corresponded well with actual outcomes.CONCLUSIONSA practical, interpretable model incorporating clinical and 123I-mIBG imaging data enabled reliable and separate prediction of HFD and ArEs, supporting personalized risk stratification in CHF.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-29DOI: 10.1007/s00259-025-07693-2
Edoardo Rosario de Natale,Heather Wilson,Joji P Verghese,Eoin Mulroy,Savvas Antoniadis,Alana Terry,Francesco Cavallieri,Micol Avenali,Pasquale Nigro,Varvara Valotassiou,Eugenii A Rabiner,Stephen Mullin,Nicola Tambasco,Maria Teresa Pellecchia,Georgia Xiromerisiou,Vicky L Marshall,Esther Sammler,Enza Maria Valente,Franco Valzania,Kailash P Bhatia,Marios Politis
{"title":"Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study.","authors":"Edoardo Rosario de Natale,Heather Wilson,Joji P Verghese,Eoin Mulroy,Savvas Antoniadis,Alana Terry,Francesco Cavallieri,Micol Avenali,Pasquale Nigro,Varvara Valotassiou,Eugenii A Rabiner,Stephen Mullin,Nicola Tambasco,Maria Teresa Pellecchia,Georgia Xiromerisiou,Vicky L Marshall,Esther Sammler,Enza Maria Valente,Franco Valzania,Kailash P Bhatia,Marios Politis","doi":"10.1007/s00259-025-07693-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07693-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"44 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-28DOI: 10.1007/s00259-025-07759-1
Giorgio Treglia, Domenico Albano, Xavier Wittebole, Andor W. J. M. Glaudemans, Janesh Pillay, Olivier Gheysens
{"title":"Diagnostic value of [18F]FDG PET/CT for detection of infectious and inflammatory foci in critically ill patients: a systematic review and meta-analysis","authors":"Giorgio Treglia, Domenico Albano, Xavier Wittebole, Andor W. J. M. Glaudemans, Janesh Pillay, Olivier Gheysens","doi":"10.1007/s00259-025-07759-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07759-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSETo compare the performance of a multidisciplinary team (MDT) with the proposed standardized PROMISE classification system for indeterminate bone uptake on staging PSMA PET.METHODS744 staging PSMA PET/CT scans (140 18F-PSMA-1007 and 604 68Ga-PSMA-11 PET/CT) were retrospectively reviewed for the presence of indeterminate bone metastatic staging. 95 scans which were discussed at an MDT meeting were further analysed for the comparison with the PROMISE classification system. MDT interpretation of the bone staging was recorded as positive or negative, based on risk stratification, imaging review, and clinically suitable management options. Additional resources were occasionally used, such as bone biopsy, musculoskeletal MRI, or re-evaluation after initial androgen deprivation therapy. MDT and PROMISE classification were compared for agreement. Statistical assessment was made on any differences in age, PSA, T-stage, Gleason score, risk, SUVmax and tracer used between negative and positive patients in both methods. Discordant cases were correlated with follow up data.RESULTSThe overall incidence of indeterminate bone uptake in staging PSMA PET scans was 16.9%, reaching 40% for 18F-PSMA-1007. There was substantial agreement between MDT and PROMISE interpretation (87.3%). The MDT was more likely to interpret an indeterminate bone uptake as negative in patients with lower Gleason score and in scans where 18F-PSMA-1007 was used. The data from long-term follow up favoured the MDT interpretation in all the cases of disagreement. Examples of pitfalls in rib or thoracic spine foci of uptake are presented and recommendations for PET reporters and MDTs have been generated based on the results.CONCLUSIONPROMISE may interpret indeterminate bone PSMA uptake with high accuracy. Therefore, PET reporters are recommended to use the PROMISE algorithm, while being mindful of common pitfalls related to the Gleason score, tracer used and anatomical localisation of indeterminate bone findings. Additional discussion in an MDT meeting is recommended with a view to resolve all equivocal findings.
{"title":"Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria.","authors":"Dimitrios Priftakis,Fadilah Aziz,Noora Bin Essa,Reena Davda,Maria Lyasheva,Sudeshna Maitra,Francesco Fraioli,Simon Wan,Jamshed Bomanji,Asim Afaq","doi":"10.1007/s00259-026-07763-z","DOIUrl":"https://doi.org/10.1007/s00259-026-07763-z","url":null,"abstract":"PURPOSETo compare the performance of a multidisciplinary team (MDT) with the proposed standardized PROMISE classification system for indeterminate bone uptake on staging PSMA PET.METHODS744 staging PSMA PET/CT scans (140 18F-PSMA-1007 and 604 68Ga-PSMA-11 PET/CT) were retrospectively reviewed for the presence of indeterminate bone metastatic staging. 95 scans which were discussed at an MDT meeting were further analysed for the comparison with the PROMISE classification system. MDT interpretation of the bone staging was recorded as positive or negative, based on risk stratification, imaging review, and clinically suitable management options. Additional resources were occasionally used, such as bone biopsy, musculoskeletal MRI, or re-evaluation after initial androgen deprivation therapy. MDT and PROMISE classification were compared for agreement. Statistical assessment was made on any differences in age, PSA, T-stage, Gleason score, risk, SUVmax and tracer used between negative and positive patients in both methods. Discordant cases were correlated with follow up data.RESULTSThe overall incidence of indeterminate bone uptake in staging PSMA PET scans was 16.9%, reaching 40% for 18F-PSMA-1007. There was substantial agreement between MDT and PROMISE interpretation (87.3%). The MDT was more likely to interpret an indeterminate bone uptake as negative in patients with lower Gleason score and in scans where 18F-PSMA-1007 was used. The data from long-term follow up favoured the MDT interpretation in all the cases of disagreement. Examples of pitfalls in rib or thoracic spine foci of uptake are presented and recommendations for PET reporters and MDTs have been generated based on the results.CONCLUSIONPROMISE may interpret indeterminate bone PSMA uptake with high accuracy. Therefore, PET reporters are recommended to use the PROMISE algorithm, while being mindful of common pitfalls related to the Gleason score, tracer used and anatomical localisation of indeterminate bone findings. Additional discussion in an MDT meeting is recommended with a view to resolve all equivocal findings.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"2 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号